1. Home
  2. TENB vs TSHA Comparison

TENB vs TSHA Comparison

Compare TENB & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenable Holdings Inc.

TENB

Tenable Holdings Inc.

HOLD

Current Price

$25.43

Market Cap

1.9B

Sector

Technology

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$5.43

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TENB
TSHA
Founded
2002
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
TENB
TSHA
Price
$25.43
$5.43
Analyst Decision
Buy
Strong Buy
Analyst Count
18
8
Target Price
$31.69
$11.63
AVG Volume (30 Days)
3.3M
2.2M
Earning Date
04-29-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
3.23
5.56
EPS
0.01
N/A
Revenue
$999,405,000.00
$9,773,000.00
Revenue This Year
$9.37
N/A
Revenue Next Year
$7.04
$1,152.42
P/E Ratio
$2,522.00
N/A
Revenue Growth
11.04
17.28
52 Week Low
$15.73
$2.25
52 Week High
$35.69
$7.30

Technical Indicators

Market Signals
Indicator
TENB
TSHA
Relative Strength Index (RSI) 75.51 40.92
Support Level $22.03 $5.37
Resistance Level $30.79 $6.02
Average True Range (ATR) 1.23 0.43
MACD 0.40 -0.23
Stochastic Oscillator 90.77 13.38

Price Performance

Historical Comparison
TENB
TSHA

About TENB Tenable Holdings Inc.

Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: